Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
EPIX Pharmaceuticals to Present Phase 2a Alzheimer's Data at Keystone Symposia
April 11th, 2008
EPIX Pharmaceuticals, Inc. (NASDAQ:EPIX), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced that Tom Megerian, M.D., Ph.D, executive director, clinical research of EPIX, is scheduled to present an oral presentation entitled "Results of a Phase 2A Study of a Novel 5HT4 Agonist for the Treatment of Alzheimer's Disease" at the Keystone Symposia Alzheimer's Disease Meeting in Keystone, Colorado on Friday, March 28, 2008 at 8:00 a.m. MDT. EPIX previously announced the compelling results of a Phase 2a clinical trial of PRX-03140 as a single...
Source: Health Business Week (2008-04-11)
|
